These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3087640)

  • 1. Absorption characteristics of macromolecular prodrugs of mitomycin C following intramuscular administration.
    Takakura Y; Mori K; Hashida M; Sezaki H
    Chem Pharm Bull (Tokyo); 1986 Apr; 34(4):1775-83. PubMed ID: 3087640
    [No Abstract]   [Full Text] [Related]  

  • 2. Absorption characteristics of the lipophilic prodrug of mitomycin C from injected liposomes or an emulsion.
    Sasaki H; Kakutani T; Hashida M; Sezaki H
    J Pharm Pharmacol; 1985 Jul; 37(7):461-5. PubMed ID: 2863347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced lymphatic delivery of mitomycin C conjugated with dextran.
    Takakura Y; Matsumoto S; Hashida M; Sezaki H
    Cancer Res; 1984 Jun; 44(6):2505-10. PubMed ID: 6202398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced delivery of mitomycin C derivatives through hairless mouse and rat skins.
    Hashida M; Mukai E; Kimura T; Sezaki H
    J Pharm Pharmacol; 1985 Aug; 37(8):542-4. PubMed ID: 2864413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood dispositions of mitomycin C and a lipophilic prodrug after intramuscular and intravenous administration in liposomes and O/W emulsion.
    Sasaki H; Kakutani T; Hashida M; Kimura T; Sezaki H
    Chem Pharm Bull (Tokyo); 1985 Jul; 33(7):2968-73. PubMed ID: 3936626
    [No Abstract]   [Full Text] [Related]  

  • 6. [Studies on the physiological disposition and pharmacokinetics of 7-N-(p-hydroxyphenyl)-mitomycin C].
    Okumura S; Deguchi T; Nakamizo N
    Jpn J Antibiot; 1982 Aug; 35(8):1967-76. PubMed ID: 7154244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental investigations on the absorption of intravesically instilled mitomycin C in the urinary bladder of the rat.
    Engelmann U; Bürger R; Jacobi GH
    Eur Urol; 1982; 8(3):176-81. PubMed ID: 6804242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tissue concentration of MMC by intra-arterial chemotherapy. Experimental study].
    Sato T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1883-4. PubMed ID: 3929696
    [No Abstract]   [Full Text] [Related]  

  • 9. Disposition and pharmacokinetics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate, in the rat.
    Hashida M; Kato A; Takakura Y; Sezaki H
    Drug Metab Dispos; 1984; 12(4):492-9. PubMed ID: 6148218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal sustained-release delivery systems for intravenous injection. II. Design of liposome carriers and blood disposition of lipophilic mitomycin C prodrug-bearing liposomes.
    Tokunaga Y; Iwasa T; Fujisaki J; Sawai S; Kagayama A
    Chem Pharm Bull (Tokyo); 1988 Sep; 36(9):3557-64. PubMed ID: 3149214
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacology of intraperitoneal infusion 5-fluorouracil and mitomycin-C.
    Gyves J
    Semin Oncol; 1985 Sep; 12(3 Suppl 4):29-32. PubMed ID: 3931225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of mitomycin C in rabbit and human.
    van Hazel GA; Kovach JS
    Cancer Chemother Pharmacol; 1982; 8(2):189-92. PubMed ID: 6809356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Permeability of the rat bladder to Cisplatinum under different conditions: comparison with Mitomycin C and Adriamycin.
    Engelmann U; Oelsner G; Bürger RA; Wagner H
    Urol Res; 1983; 11(1):39-42. PubMed ID: 6407169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution and excretion of 7-N-(p-hydroxyphenyl)-mitomycin C in normal mice.
    Imai R; Morimoto M; Marumo H
    Gan; 1982 Aug; 73(4):675-80. PubMed ID: 6818093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of the cytocidal effect of mitomycin C by means of simultaneous administration of prostaglandin E1.
    Ichihashi H; Kuzuya H; Kondo T
    Gan; 1983 Feb; 74(1):169-75. PubMed ID: 6404685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.
    van Hazel GA; Scott M; Rubin J; Moertel CG; Eagan RT; O'Connell MJ; Kovach JS
    Cancer Treat Rep; 1983 Sep; 67(9):805-10. PubMed ID: 6411337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of deoxyribonucleic acid with reductively activated mitomycin C. Structures of modified nucleotides.
    Hashimoto Y; Shudo K; Okamoto T
    Chem Pharm Bull (Tokyo); 1983 Mar; 31(3):861-9. PubMed ID: 6411371
    [No Abstract]   [Full Text] [Related]  

  • 18. [Topical application of mitomycin C conjugated with dextran (MMC-D): a high molecular weight derivative of mitomycin C].
    Honda K; Satomura K; Hashida M; Sezaki H
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):530-5. PubMed ID: 2408576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regeneration characteristics of mitomycin C-dextran conjugate in relation to its activity.
    Hashida M; Takakura Y; Matsumoto S; Sasaki H; Kato A; Kojima T; Muranishi S; Sezaki H
    Chem Pharm Bull (Tokyo); 1983 Jun; 31(6):2055-63. PubMed ID: 6196134
    [No Abstract]   [Full Text] [Related]  

  • 20. Production of a monoclonal antibody-mitomycin C conjugate, utilizing dextran T-40, and its biological activity.
    Manabe Y; Tsubota T; Haruta Y; Kataoka K; Okazaki M; Haisa S; Nakamura K; Kimura I
    Biochem Pharmacol; 1985 Jan; 34(2):289-91. PubMed ID: 2578281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.